Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-845-579-5705

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

T: +1-347-918-3531

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Keratitis Treatment Market Snapshot (2023 to 2033)

The global keratitis treatment market is expected to surpass an impressive valuation of US$ 789.89 million in 2023 and is projected to exhibit a CAGR of 6% from 2023 to 2033.

The rising incidence of contagious diseases is driving the keratitis treatment market. The disease becomes more prevalent as the temperature goes up. Furthermore, it has been discovered to be common in tropical regions, so a rise in global temperature influences the incidence of keratitis, thereby propelling the market. Despite being treatable, this is the most prevalent trigger of corneal blindness caused by an infection in the United States. In the United States, the incidence of neurotrophic keratitis (NK) varies from 56 to 67 cases per 100,000 individuals.

The disease is spreading as a result of poor sanitary conditions in developing nations. Wearing contact lenses while swimming is another aspect that is ramping up contamination in the eye, which is contributing to the expansion of the keratitis treatment market. In advanced economies, such as North America, modernization and contact lens use are the most common causes of keratitis. Individuals living in developing countries remote regions are likely to be affected by the disease because they lack access to healthcare providers due to low revenues.

The Asia Pacific market is projected to expand owing to the rapid boost in the number of educational campaigns and the citizenry affected by fungal keratitis. Furthermore, approaches by governments in the region to improve medical facilities for the community aid in the expansion of fungal keratitis treatment. The usage of new medicines and R&D in regions such as Asia Pacific and Latin America is also expected to fuel business growth over the coming years.

According to the latest report by News Medical Life Sciences, roughly 25,000 individuals in the United States develop bacterial keratitis every year. The prevalence varies around the world, but it is more common in industrialized nations owing to the significantly greater number of individuals who wear contact lenses, which raises the likelihood of the ailment. Acanthamoeba keratitis is an exceedingly rare but fatal eye infection another type of this disease. Experts predict that 1 to 33 trusted Source contact lens-wearing people per million in developed nations are affected each year

The global demand for keratitis treatment is being influenced by increasing medical spending. Moreover, there have been few advancements in keratitis treatment, limiting sales growth. With major investments, the keratitis treatment market provides the opportunity to detect coronary eye disease and retains a good perception throughout the coming years. Also, the disease is spreading as a result of poor sanitary conditions in developing nations. Wearing contact lenses while swimming is another aspect contributing to increased contamination in the eye, which itself is fuelling the expansion of the keratitis treatment market.

According to reports, researchers created a nanoparticle-based drug delivery system that enhances drug retention time by aligning the cornea, decreasing inflammation, and releasing anti-fungal medication in response to external factors. Infected eyes show substantially greater corneal longevity, lowered in?ammatory, and infection resolution. Such research breakthroughs have produced numerous continuous innovations of extremely effective drugs against different keratitis ailments, resulting in the bulk of investors preferring to invest in R&D and contribute to the growing market. Considering the aforementioned facts and figures, the market is projected to exhibit a good rate of growth.

Report Attribute Details
Expected Market Value (2023) US$ 789.89 Million
Anticipated Forecast Value (2033) US$ 1,499.45 Million
Projected Growth Rate (2023 to 2033) 6% CAGR

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2018 2022 to Keratitis Treatment Demand Analysis vs. Forecast 2023-2033

During the initial phase of 2020, a restrictively monitored public health strategy comprised of travel restrictions and overall closures was incorporated on a large scale. Nevertheless, a slew of consequences was unavoidable. Minimizing doctor visits and consequently decreasing prescriptions were two of the most common methods for limiting the spread of COVID-19. Regardless of the fact that a number of drugs have been licensed for sale in the keratitis treatment market, production was impeded due to the pandemic in historical decades. From 2017 to 2022, sales witnessed significant growth, registering a CAGR of 5.1%.

As the number of people who use contact lenses grows, so does the incidence of keratitis. The most typical risk factors for infection include the wearing of contact lenses, linked poor hygiene, and exposure to amoeba-infested waterways. As a result of the factors mentioned, it is definite that the prevalence of keratitis is rising, which is expected to aid in the expansion of the researched market during the coming decades.

Which are Some Prominent Drivers of the Keratitis Treatment Market?

The growing prevalence of keratitis and product development propels growth of the market

The increasing prevalence of fungal keratitis and product innovation are predicted to propel the expansion of the fungal keratitis treatment market. Scientists found the average worldwide prevalence of fungal keratitis to be around one million cases, with 8% to 11% of patients losing an eye, based on the article "Global Epidemiology of Fungal Keratitis and Its Outcomes" released in January 2021.

Trauma, contact lens utilization, topical corticosteroid use, Diabetes mellitus, and low socioeconomic background are all major risk factors for fungal keratitis. The most frequent risk factor for fungal keratitis is unquestionably unintended ocular trauma.

Topical Drugs Expected to Propel Growth Rate in the industry

The most frequently used medications for the treatment of fungal keratitis are topical antifungals, which are either widely viable or exacerbated from systemic preparations into eye drops. Natamycin is the only FDA-approved topical antifungal remedy for fungal keratitis.

With increasing technological developments and trials, new effective drug delivery systems like drug-eluting contact lenses are gaining popularity. The topical route of management, on the other hand, is predicted to expand significantly over the period due to the creation of new topical formulations as the solely authorized medicine for fungal keratitis.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What are the Challenges Projected to be Faced by the Market?

Poor reimbursement scenarios and high costs hamper the market growth

Non-favorable reimbursement scenarios in emerging and underdeveloped economies, on the other hand, will pose a significant threat to industry growth.

Treatment for this ailment either alters the eye or its operation or increases the rate of market expansion. The high costs incurred with the prolonged usage of topical eye gels and drops might further deter overall growth.

Region-Wise Insights

What Makes North America the Largest Market for Keratitis Treatment?

North America to dominate the Keratitis Treatment Market

Since rising keratitis scenarios and the latest developments in keratitis treatment, North America is predicted to lead the keratitis treatment market. Due to a large number of keratitis patients and other prolonged eye diseases, as well as soaring expenditure on research and development the United States is anticipated to overtake the total keratitis treatment market in the North American region across the forecast timeframe.

Fungal keratitis is quite prevalent in warm and moist areas of the United States. According to a research released in October 2020 titled "The global incidence and diagnosis of fungal keratitis," the southern part of the United States has a greater incidence of keratitis than other regions.

Why is Asia Pacific Considered a Lucrative Region for the Keratitis Treatment market?

Asia-Pacific to emerge as the industry’s second-largest region

Asia-Pacific is the second most important region, with a market worth US$ 200 million in 2021 and a CAGR of 7.1%. This is due to increasing healthcare system infrastructure construction costs and a growing geriatric population. Besides that, favorable trial results may lead to a new diagnosis, which is likely to accelerate market growth in the coming timeframe.

Aravind Eye Care System in India, for instance, was conducting a randomized control trial with topical anti-fungal treatment in 2021 to evaluate the graphic and clinical results of collagen cross-linking in keratitis. The study's goal is to determine the function of corneal cross-linking in the preventative measures of perforation and the advancement of the treatment regimen in non-resolving fungal keratitis. As a consequence of the aforementioned components, the researched market is likely to contribute to industry growth in Asia Pacific.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-Wise Insights

Which Type Keratitis Segment to Garner High Market Share?

Asia Pacific has a large number of Infectious keratitis patients

Infectious keratitis is the fifth leading reason of blindness worldwide. Contact lens wear, eye injury, and retinal disease are the main risk factors. In Asia, where infectious keratitis is a threat to public health, the situation is drastically different.

These countries are having barriers to treatment, poor health metrics, and a larger portion of laborers in agriculture activities, with occurrences as elevated as 113 per 100,000 in Madurai, Tamil Nadu, India. As a result, the infectious keratitis segment is expected to grow significantly in the upcoming years.

Start-ups offering Keratitis Treatment Solutions

Prominent start-up players in the keratitis treatment market sector are introducing novel and innovative product lines to strengthen their market presence, and the aforementioned start-ups have left no stone unturned. The following are some specific examples of significant keratitis treatment market start-ups:

  • Yas Holding is a private equity company based in Abu Dhabi, United Arab Emirates, that was established in 2006. Alvogen and Yas Holding declared a license and dispersion accord to commercialize the generics portfolio in April 2020.
  • Eyevance, established in 2017, is a distributor of ophthalmic products and therapies that approach unmet medical requirements. Tobradex ST was acquired by Eyevance Pharmaceuticals LLC in October 2019 for future global expansion.

Market Competition

Key players in the Keratitis Treatment market are Alvogen, Bausch health Companies Inc, Gilead Biosciences Inc, Glenmark Pharmaceuticals, Leadiant Biosciences, Merck & Co. Inc., Aurolab, Eyevance Pharmaceuticals LLC, Pfizer Inc, Novartis AG. Some of the latest developments by key players are below

  • Pfizer Inc. accomplished the contract to spin off its Upjohn Business and merge it with Mylan N.V. to form Viatris Inc. in November 2020.
  • Bausch Health Companies Inc. signed a contract in September 2020 to acquire an opportunity to buy all of Allegro Ophthalmics' ophthalmology resources.

Report Scope

Report Attribute Details
Market Value in 2023 US$ 789.89 Million
Market Value in 2033 US$ 1,499.45 Million
Growth Rate CAGR of 6% from 2023 to 2033
Base Year for Estimation 2022
Historical Data 2017 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in US$ Million and CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered
  • Keratitis Types
  • Treatment
  • End Users
  • Region
Regions Covered
  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East & Africa
Key Countries Profiled
  • United States
  • Canada
  • Brazil
  • Mexico
  • Germany
  • United Kingdom
  • France
  • Spain
  • Italy
  • India
  • Malaysia
  • Singapore
  • Thailand
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • GCC Countries
  • South Africa
  • Israel
Key Companies Profiled
  • Alvogen
  • Bausch Health Companies Inc.
  • Gilead Biosciences Inc.
  • Glenmark Pharmaceuticals
  • Leadiant Biosciences
  • Merck & Co. Inc.
  • Aurolab
  • Eyevance Pharmaceuticals LLC
  • Pfizer Inc.
  • Novartis AG
Customization Available Upon Request

Key Segments Profiled in the Keratitis Treatment Market Industry Survey

By Keratitis Types:

  • Noninfectious Keratitis
  • Infectious Keratitis
    • Bacterial Keratitis
    • Fungal Keratitis
    • Viral Keratitis
    • Acanthamoeba Keratitis

By Treatment:

  • Topical Antibiotics
  • Antifungals
  • Antiviral
  • Biocides

By End Users:

  • Hospitals
  • Specialty Clinics

By Region:

  • North America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Latin America
  • Middle East and Africa

Frequently Asked Questions

What is the market size by 2033?

The market is set to reach US$ 1,499.45 million by 2033.

What was the historical size of the market?

A CAGR of 5.1% was observed in the market from 2017 to 2022.

Who are some prominent keratitis treatment market players?

Alvogen, Bausch Health Companies Inc., and Gilead Biosciences Inc.

What is the anticipated growth of the market?

By 2033, the market is projected to register a value CAGR of 6%.

Which region is forecast to have the maximum growth rate?

North America is expected to lead the market.

Table of Content

1. Executive Summary | Keratitis Treatment Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Keratitis Types

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Keratitis Types, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Keratitis Types, 2023 to 2033

        5.3.1. Non-infectious Keratitis

        5.3.2. Infectious Keratitis

            5.3.2.1. Bacterial Keratitis

            5.3.2.2. Fungal Keratitis

            5.3.2.3. Viral Keratitis

            5.3.2.4. Acanthamoeba Keratitis

    5.4. Y-o-Y Growth Trend Analysis By Keratitis Types, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Keratitis Types, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033

        6.3.1. Topical Antibiotics

        6.3.2. Antifungals

        6.3.3. Antivirals

        6.3.4. Biocides

    6.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End Users 

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By End Users , 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End Users , 2023 to 2033

        7.3.1. Hospitals

        7.3.2. Specialty Clinics

    7.4. Y-o-Y Growth Trend Analysis By End Users , 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By End Users , 2023 to 2033

8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Europe

        8.3.4. South Asia

        8.3.5. East Asia

        8.3.6. Oceania

        8.3.7. MEA

    8.4. Market Attractiveness Analysis By Region

9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. USA

            9.2.1.2. Canada

        9.2.2. By Keratitis Types

        9.2.3. By Treatment

        9.2.4. By End Users

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Keratitis Types

        9.3.3. By Treatment

        9.3.4. By End Users

    9.4. Key Takeaways

10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Rest of Latin America

        10.2.2. By Keratitis Types

        10.2.3. By Treatment

        10.2.4. By End Users

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Keratitis Types

        10.3.3. By Treatment

        10.3.4. By End Users

    10.4. Key Takeaways

11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Germany

            11.2.1.2. United Kingdom

            11.2.1.3. France

            11.2.1.4. Spain

            11.2.1.5. Italy

            11.2.1.6. Rest of Europe

        11.2.2. By Keratitis Types

        11.2.3. By Treatment

        11.2.4. By End Users

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Keratitis Types

        11.3.3. By Treatment

        11.3.4. By End Users

    11.4. Key Takeaways

12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. India

            12.2.1.2. Malaysia

            12.2.1.3. Singapore

            12.2.1.4. Thailand

            12.2.1.5. Rest of South Asia

        12.2.2. By Keratitis Types

        12.2.3. By Treatment

        12.2.4. By End Users

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Keratitis Types

        12.3.3. By Treatment

        12.3.4. By End Users

    12.4. Key Takeaways

13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. China

            13.2.1.2. Japan

            13.2.1.3. South Korea

        13.2.2. By Keratitis Types

        13.2.3. By Treatment

        13.2.4. By End Users

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Keratitis Types

        13.3.3. By Treatment

        13.3.4. By End Users

    13.4. Key Takeaways

14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. Australia

            14.2.1.2. New Zealand

        14.2.2. By Keratitis Types

        14.2.3. By Treatment

        14.2.4. By End Users

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Keratitis Types

        14.3.3. By Treatment

        14.3.4. By End Users

    14.4. Key Takeaways

15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        15.2.1. By Country

            15.2.1.1. GCC Countries

            15.2.1.2. South Africa

            15.2.1.3. Israel

            15.2.1.4. Rest of MEA

        15.2.2. By Keratitis Types

        15.2.3. By Treatment

        15.2.4. By End Users

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Keratitis Types

        15.3.3. By Treatment

        15.3.4. By End Users

    15.4. Key Takeaways

16. Key Countries Market Analysis

    16.1. USA

        16.1.1. Pricing Analysis

        16.1.2. Market Share Analysis, 2022

            16.1.2.1. By Keratitis Types

            16.1.2.2. By Treatment

            16.1.2.3. By End Users

    16.2. Canada

        16.2.1. Pricing Analysis

        16.2.2. Market Share Analysis, 2022

            16.2.2.1. By Keratitis Types

            16.2.2.2. By Treatment

            16.2.2.3. By End Users

    16.3. Brazil

        16.3.1. Pricing Analysis

        16.3.2. Market Share Analysis, 2022

            16.3.2.1. By Keratitis Types

            16.3.2.2. By Treatment

            16.3.2.3. By End Users

    16.4. Mexico

        16.4.1. Pricing Analysis

        16.4.2. Market Share Analysis, 2022

            16.4.2.1. By Keratitis Types

            16.4.2.2. By Treatment

            16.4.2.3. By End Users

    16.5. Germany

        16.5.1. Pricing Analysis

        16.5.2. Market Share Analysis, 2022

            16.5.2.1. By Keratitis Types

            16.5.2.2. By Treatment

            16.5.2.3. By End Users

    16.6. United Kingdom(UK)

        16.6.1. Pricing Analysis

        16.6.2. Market Share Analysis, 2022

            16.6.2.1. By Keratitis Types

            16.6.2.2. By Treatment

            16.6.2.3. By End Users

    16.7. France

        16.7.1. Pricing Analysis

        16.7.2. Market Share Analysis, 2022

            16.7.2.1. By Keratitis Types

            16.7.2.2. By Treatment

            16.7.2.3. By End Users

    16.8. Spain

        16.8.1. Pricing Analysis

        16.8.2. Market Share Analysis, 2022

            16.8.2.1. By Keratitis Types

            16.8.2.2. By Treatment

            16.8.2.3. By End Users

    16.9. Italy

        16.9.1. Pricing Analysis

        16.9.2. Market Share Analysis, 2022

            16.9.2.1. By Keratitis Types

            16.9.2.2. By Treatment

            16.9.2.3. By End Users

    16.10. India

        16.10.1. Pricing Analysis

        16.10.2. Market Share Analysis, 2022

            16.10.2.1. By Keratitis Types

            16.10.2.2. By Treatment

            16.10.2.3. By End Users

    16.11. Malaysia

        16.11.1. Pricing Analysis

        16.11.2. Market Share Analysis, 2022

            16.11.2.1. By Keratitis Types

            16.11.2.2. By Treatment

            16.11.2.3. By End Users

    16.12. Singapore

        16.12.1. Pricing Analysis

        16.12.2. Market Share Analysis, 2022

            16.12.2.1. By Keratitis Types

            16.12.2.2. By Treatment

            16.12.2.3. By End Users

    16.13. Thailand

        16.13.1. Pricing Analysis

        16.13.2. Market Share Analysis, 2022

            16.13.2.1. By Keratitis Types

            16.13.2.2. By Treatment

            16.13.2.3. By End Users

    16.14. China

        16.14.1. Pricing Analysis

        16.14.2. Market Share Analysis, 2022

            16.14.2.1. By Keratitis Types

            16.14.2.2. By Treatment

            16.14.2.3. By End Users

    16.15. Japan

        16.15.1. Pricing Analysis

        16.15.2. Market Share Analysis, 2022

            16.15.2.1. By Keratitis Types

            16.15.2.2. By Treatment

            16.15.2.3. By End Users

    16.16. South Korea

        16.16.1. Pricing Analysis

        16.16.2. Market Share Analysis, 2022

            16.16.2.1. By Keratitis Types

            16.16.2.2. By Treatment

            16.16.2.3. By End Users

    16.17. Australia

        16.17.1. Pricing Analysis

        16.17.2. Market Share Analysis, 2022

            16.17.2.1. By Keratitis Types

            16.17.2.2. By Treatment

            16.17.2.3. By End Users

    16.18. New Zealand

        16.18.1. Pricing Analysis

        16.18.2. Market Share Analysis, 2022

            16.18.2.1. By Keratitis Types

            16.18.2.2. By Treatment

            16.18.2.3. By End Users

    16.19. GCC Countries

        16.19.1. Pricing Analysis

        16.19.2. Market Share Analysis, 2022

            16.19.2.1. By Keratitis Types

            16.19.2.2. By Treatment

            16.19.2.3. By End Users

    16.20. South Africa

        16.20.1. Pricing Analysis

        16.20.2. Market Share Analysis, 2022

            16.20.2.1. By Keratitis Types

            16.20.2.2. By Treatment

            16.20.2.3. By End Users

    16.21. Israel

        16.21.1. Pricing Analysis

        16.21.2. Market Share Analysis, 2022

            16.21.2.1. By Keratitis Types

            16.21.2.2. By Treatment

            16.21.2.3. By End Users

17. Market Structure Analysis

    17.1. Competition Dashboard

    17.2. Competition Benchmarking

    17.3. Market Share Analysis of Top Players

        17.3.1. By Regional

        17.3.2. By Keratitis Types

        17.3.3. By Treatment

        17.3.4. By End Users

18. Competition Analysis

    18.1. Competition Deep Dive

        18.1.1. Alvogen

            18.1.1.1. Overview

            18.1.1.2. Product Portfolio

            18.1.1.3. Profitability by Market Segments

            18.1.1.4. Sales Footprint

            18.1.1.5. Strategy Overview

                18.1.1.5.1. Marketing Strategy

        18.1.2. Bausch Health Companies Inc.

            18.1.2.1. Overview

            18.1.2.2. Product Portfolio

            18.1.2.3. Profitability by Market Segments

            18.1.2.4. Sales Footprint

            18.1.2.5. Strategy Overview

                18.1.2.5.1. Marketing Strategy

        18.1.3. Gilead Biosciences Inc.

            18.1.3.1. Overview

            18.1.3.2. Product Portfolio

            18.1.3.3. Profitability by Market Segments

            18.1.3.4. Sales Footprint

            18.1.3.5. Strategy Overview

                18.1.3.5.1. Marketing Strategy

        18.1.4. Glenmark Pharmaceuticals

            18.1.4.1. Overview

            18.1.4.2. Product Portfolio

            18.1.4.3. Profitability by Market Segments

            18.1.4.4. Sales Footprint

            18.1.4.5. Strategy Overview

                18.1.4.5.1. Marketing Strategy

        18.1.5. Leadiant Biosciences

            18.1.5.1. Overview

            18.1.5.2. Product Portfolio

            18.1.5.3. Profitability by Market Segments

            18.1.5.4. Sales Footprint

            18.1.5.5. Strategy Overview

                18.1.5.5.1. Marketing Strategy

        18.1.6. Merck & Co. Inc.

            18.1.6.1. Overview

            18.1.6.2. Product Portfolio

            18.1.6.3. Profitability by Market Segments

            18.1.6.4. Sales Footprint

            18.1.6.5. Strategy Overview

                18.1.6.5.1. Marketing Strategy

        18.1.7. Aurolab

            18.1.7.1. Overview

            18.1.7.2. Product Portfolio

            18.1.7.3. Profitability by Market Segments

            18.1.7.4. Sales Footprint

            18.1.7.5. Strategy Overview

                18.1.7.5.1. Marketing Strategy

        18.1.8. Eyevance Pharmaceuticals LLC

            18.1.8.1. Overview

            18.1.8.2. Product Portfolio

            18.1.8.3. Profitability by Market Segments

            18.1.8.4. Sales Footprint

            18.1.8.5. Strategy Overview

                18.1.8.5.1. Marketing Strategy

        18.1.9. Pfizer Inc

            18.1.9.1. Overview

            18.1.9.2. Product Portfolio

            18.1.9.3. Profitability by Market Segments

            18.1.9.4. Sales Footprint

            18.1.9.5. Strategy Overview

                18.1.9.5.1. Marketing Strategy

        18.1.10. Novartis AG

            18.1.10.1. Overview

            18.1.10.2. Product Portfolio

            18.1.10.3. Profitability by Market Segments

            18.1.10.4. Sales Footprint

            18.1.10.5. Strategy Overview

                18.1.10.5.1. Marketing Strategy

19. Assumptions & Acronyms Used

20. Research Methodology

List of Tables

Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033

Table 2: Global Market Value (US$ Million) Forecast by Keratitis Types, 2018 to 2033

Table 3: Global Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 4: Global Market Value (US$ Million) Forecast by End User , 2018 to 2033

Table 5: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 6: North America Market Value (US$ Million) Forecast by Keratitis Types, 2018 to 2033

Table 7: North America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 8: North America Market Value (US$ Million) Forecast by End Users , 2018 to 2033

Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 10: Latin America Market Value (US$ Million) Forecast by Keratitis Types, 2018 to 2033

Table 11: Latin America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 12: Latin America Market Value (US$ Million) Forecast by End Users , 2018 to 2033

Table 13: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 14: Europe Market Value (US$ Million) Forecast by Keratitis Types, 2018 to 2033

Table 15: Europe Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 16: Europe Market Value (US$ Million) Forecast by End Users , 2018 to 2033

Table 17: South Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 18: South Asia Market Value (US$ Million) Forecast by Keratitis Types, 2018 to 2033

Table 19: South Asia Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 20: South Asia Market Value (US$ Million) Forecast by End Users , 2018 to 2033

Table 21: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 22: East Asia Market Value (US$ Million) Forecast by Keratitis Types, 2018 to 2033

Table 23: East Asia Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 24: East Asia Market Value (US$ Million) Forecast by End Users, 2018 to 2033

Table 25: Oceania Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 26: Oceania Market Value (US$ Million) Forecast by Keratitis Types, 2018 to 2033

Table 27: Oceania Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 28: Oceania Market Value (US$ Million) Forecast by End Users, 2018 to 2033

Table 29: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 30: MEA Market Value (US$ Million) Forecast by Keratitis Types, 2018 to 2033

Table 31: MEA Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 32: MEA Market Value (US$ Million) Forecast by End Users, 2018 to 2033

List of Charts

Figure 1: Global Market Value (US$ Million) by Keratitis Types, 2023 to 2033

Figure 2: Global Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 3: Global Market Value (US$ Million) by End Users , 2023 to 2033

Figure 4: Global Market Value (US$ Million) by Region, 2023 to 2033

Figure 5: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033

Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033

Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033

Figure 8: Global Market Value (US$ Million) Analysis by Keratitis Types, 2018 to 2033

Figure 9: Global Market Value Share (%) and BPS Analysis by Keratitis Types, 2023 to 2033

Figure 10: Global Market Y-o-Y Growth (%) Projections by Keratitis Types, 2023 to 2033

Figure 11: Global Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 12: Global Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 13: Global Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 14: Global Market Value (US$ Million) Analysis by End Users , 2018 to 2033

Figure 15: Global Market Value Share (%) and BPS Analysis by End Users , 2023 to 2033

Figure 16: Global Market Y-o-Y Growth (%) Projections by End Users , 2023 to 2033

Figure 17: Global Market Attractiveness by Keratitis Types, 2023 to 2033

Figure 18: Global Market Attractiveness by Treatment, 2023 to 2033

Figure 19: Global Market Attractiveness by End Users , 2023 to 2033

Figure 20: Global Market Attractiveness by Region, 2023 to 2033

Figure 21: North America Market Value (US$ Million) by Keratitis Types, 2023 to 2033

Figure 22: North America Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 23: North America Market Value (US$ Million) by End Users , 2023 to 2033

Figure 24: North America Market Value (US$ Million) by Country, 2023 to 2033

Figure 25: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 28: North America Market Value (US$ Million) Analysis by Keratitis Types, 2018 to 2033

Figure 29: North America Market Value Share (%) and BPS Analysis by Keratitis Types, 2023 to 2033

Figure 30: North America Market Y-o-Y Growth (%) Projections by Keratitis Types, 2023 to 2033

Figure 31: North America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 32: North America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 33: North America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 34: North America Market Value (US$ Million) Analysis by End Users , 2018 to 2033

Figure 35: North America Market Value Share (%) and BPS Analysis by End Users , 2023 to 2033

Figure 36: North America Market Y-o-Y Growth (%) Projections by End Users , 2023 to 2033

Figure 37: North America Market Attractiveness by Keratitis Types, 2023 to 2033

Figure 38: North America Market Attractiveness by Treatment, 2023 to 2033

Figure 39: North America Market Attractiveness by End Users , 2023 to 2033

Figure 40: North America Market Attractiveness by Country, 2023 to 2033

Figure 41: Latin America Market Value (US$ Million) by Keratitis Types, 2023 to 2033

Figure 42: Latin America Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 43: Latin America Market Value (US$ Million) by End Users , 2023 to 2033

Figure 44: Latin America Market Value (US$ Million) by Country, 2023 to 2033

Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 48: Latin America Market Value (US$ Million) Analysis by Keratitis Types, 2018 to 2033

Figure 49: Latin America Market Value Share (%) and BPS Analysis by Keratitis Types, 2023 to 2033

Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Keratitis Types, 2023 to 2033

Figure 51: Latin America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 52: Latin America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 54: Latin America Market Value (US$ Million) Analysis by End Users , 2018 to 2033

Figure 55: Latin America Market Value Share (%) and BPS Analysis by End Users , 2023 to 2033

Figure 56: Latin America Market Y-o-Y Growth (%) Projections by End Users , 2023 to 2033

Figure 57: Latin America Market Attractiveness by Keratitis Types, 2023 to 2033

Figure 58: Latin America Market Attractiveness by Treatment, 2023 to 2033

Figure 59: Latin America Market Attractiveness by End Users , 2023 to 2033

Figure 60: Latin America Market Attractiveness by Country, 2023 to 2033

Figure 61: Europe Market Value (US$ Million) by Keratitis Types, 2023 to 2033

Figure 62: Europe Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 63: Europe Market Value (US$ Million) by End Users , 2023 to 2033

Figure 64: Europe Market Value (US$ Million) by Country, 2023 to 2033

Figure 65: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 68: Europe Market Value (US$ Million) Analysis by Keratitis Types, 2018 to 2033

Figure 69: Europe Market Value Share (%) and BPS Analysis by Keratitis Types, 2023 to 2033

Figure 70: Europe Market Y-o-Y Growth (%) Projections by Keratitis Types, 2023 to 2033

Figure 71: Europe Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 72: Europe Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 73: Europe Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 74: Europe Market Value (US$ Million) Analysis by End Users , 2018 to 2033

Figure 75: Europe Market Value Share (%) and BPS Analysis by End Users , 2023 to 2033

Figure 76: Europe Market Y-o-Y Growth (%) Projections by End Users , 2023 to 2033

Figure 77: Europe Market Attractiveness by Keratitis Types, 2023 to 2033

Figure 78: Europe Market Attractiveness by Treatment, 2023 to 2033

Figure 79: Europe Market Attractiveness by End Users , 2023 to 2033

Figure 80: Europe Market Attractiveness by Country, 2023 to 2033

Figure 81: South Asia Market Value (US$ Million) by Keratitis Types, 2023 to 2033

Figure 82: South Asia Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 83: South Asia Market Value (US$ Million) by End Users , 2023 to 2033

Figure 84: South Asia Market Value (US$ Million) by Country, 2023 to 2033

Figure 85: South Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 86: South Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 87: South Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 88: South Asia Market Value (US$ Million) Analysis by Keratitis Types, 2018 to 2033

Figure 89: South Asia Market Value Share (%) and BPS Analysis by Keratitis Types, 2023 to 2033

Figure 90: South Asia Market Y-o-Y Growth (%) Projections by Keratitis Types, 2023 to 2033

Figure 91: South Asia Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 92: South Asia Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 93: South Asia Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 94: South Asia Market Value (US$ Million) Analysis by End Users , 2018 to 2033

Figure 95: South Asia Market Value Share (%) and BPS Analysis by End Users , 2023 to 2033

Figure 96: South Asia Market Y-o-Y Growth (%) Projections by End Users , 2023 to 2033

Figure 97: South Asia Market Attractiveness by Keratitis Types, 2023 to 2033

Figure 98: South Asia Market Attractiveness by Treatment, 2023 to 2033

Figure 99: South Asia Market Attractiveness by End Users , 2023 to 2033

Figure 100: South Asia Market Attractiveness by Country, 2023 to 2033

Figure 101: East Asia Market Value (US$ Million) by Keratitis Types, 2023 to 2033

Figure 102: East Asia Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 103: East Asia Market Value (US$ Million) by End Users , 2023 to 2033

Figure 104: East Asia Market Value (US$ Million) by Country, 2023 to 2033

Figure 105: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 106: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 107: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 108: East Asia Market Value (US$ Million) Analysis by Keratitis Types, 2018 to 2033

Figure 109: East Asia Market Value Share (%) and BPS Analysis by Keratitis Types, 2023 to 2033

Figure 110: East Asia Market Y-o-Y Growth (%) Projections by Keratitis Types, 2023 to 2033

Figure 111: East Asia Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 112: East Asia Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 113: East Asia Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 114: East Asia Market Value (US$ Million) Analysis by End Users , 2018 to 2033

Figure 115: East Asia Market Value Share (%) and BPS Analysis by End Users , 2023 to 2033

Figure 116: East Asia Market Y-o-Y Growth (%) Projections by End Users , 2023 to 2033

Figure 117: East Asia Market Attractiveness by Keratitis Types, 2023 to 2033

Figure 118: East Asia Market Attractiveness by Treatment, 2023 to 2033

Figure 119: East Asia Market Attractiveness by End Users , 2023 to 2033

Figure 120: East Asia Market Attractiveness by Country, 2023 to 2033

Figure 121: Oceania Market Value (US$ Million) by Keratitis Types, 2023 to 2033

Figure 122: Oceania Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 123: Oceania Market Value (US$ Million) by End Users , 2023 to 2033

Figure 124: Oceania Market Value (US$ Million) by Country, 2023 to 2033

Figure 125: Oceania Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 126: Oceania Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 127: Oceania Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 128: Oceania Market Value (US$ Million) Analysis by Keratitis Types, 2018 to 2033

Figure 129: Oceania Market Value Share (%) and BPS Analysis by Keratitis Types, 2023 to 2033

Figure 130: Oceania Market Y-o-Y Growth (%) Projections by Keratitis Types, 2023 to 2033

Figure 131: Oceania Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 132: Oceania Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 133: Oceania Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 134: Oceania Market Value (US$ Million) Analysis by End Users , 2018 to 2033

Figure 135: Oceania Market Value Share (%) and BPS Analysis by End Users , 2023 to 2033

Figure 136: Oceania Market Y-o-Y Growth (%) Projections by End Users , 2023 to 2033

Figure 137: Oceania Market Attractiveness by Keratitis Types, 2023 to 2033

Figure 138: Oceania Market Attractiveness by Treatment, 2023 to 2033

Figure 139: Oceania Market Attractiveness by End Users , 2023 to 2033

Figure 140: Oceania Market Attractiveness by Country, 2023 to 2033

Figure 141: MEA Market Value (US$ Million) by Keratitis Types, 2023 to 2033

Figure 142: MEA Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 143: MEA Market Value (US$ Million) by End Users , 2023 to 2033

Figure 144: MEA Market Value (US$ Million) by Country, 2023 to 2033

Figure 145: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 146: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 147: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 148: MEA Market Value (US$ Million) Analysis by Keratitis Types, 2018 to 2033

Figure 149: MEA Market Value Share (%) and BPS Analysis by Keratitis Types, 2023 to 2033

Figure 150: MEA Market Y-o-Y Growth (%) Projections by Keratitis Types, 2023 to 2033

Figure 151: MEA Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 152: MEA Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 153: MEA Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 154: MEA Market Value (US$ Million) Analysis by End Users , 2018 to 2033

Figure 155: MEA Market Value Share (%) and BPS Analysis by End Users , 2023 to 2033

Figure 156: MEA Market Y-o-Y Growth (%) Projections by End Users , 2023 to 2033

Figure 157: MEA Market Attractiveness by Keratitis Types, 2023 to 2033

Figure 158: MEA Market Attractiveness by Treatment, 2023 to 2033

Figure 159: MEA Market Attractiveness by End Users , 2023 to 2033

Figure 160: MEA Market Attractiveness by Country, 2023 to 2033

Recommendations

Healthcare

Fungal Keratitis Treatment Market

Published : August 2023

Healthcare

Herpes Simplex Keratitis Treatment Market

Published : August 2023

Healthcare

Bionic Eye Market

Published : November 2022

Healthcare

Eye Infections Treatment Market

Published : July 2022

Explore Healthcare Insights

View Reports

Keratitis Treatment Market